1. New Horizons in Cystic Fibrosis Clinical Developments From Fall 2014

2. New Data on Mutation-Targeting Therapies and Antibiotics

3. Combining Lumicaftor and Ivacaftor: The Results of TRAFFIC and TRANSPORTa,b

4. Methods

5. Results

6. Results (cont)

7. Summary

8. Study of an Investigational S-Nitroglutathione Reductase Inhibitor

9. Methods

10. Results

11. Results (cont)

12. Doxycycline Adjunctive Therapy

13. Methods

14. Clinical Results

15. Bioactivity Results

16. Conclusions

17. Reports on Investigational Mucolytic Agents and CFTR-Directed Therapies

18. Study of a Novel Mucolytic Agent

19. Assessing Viscosity

20. Assessing Transportability

21. Investigational CFTR Corrector Added to Ivacaftor Treatment

22. Methods

23. Methods and Results

24. Mean Within-Group Changes (Days 0 to 28)

25. Take-Home Points

26. Recent Reports on Pseudomonas Incidence and Treatment

27. Respiratory Microbiologic Trends

28. Methods and Results

29. Results

30. Results (cont)

31. Long-Term Data From EPIC Study

32. Results

33. Conclusions

34. Predictors of Response to Antibiotic Treatment for Pulmonary Exacerbations

35. Results (cont)

36. Conclusions

37. Introducing the STOP Study on Pulmonary Exacerbations

38. The STOP Study

39. Methods

40. Results

41. Physician Willingness to Enroll Patients in Interventional Trials

42. Preexacerbation Clinical Characteristics: STOP

43. Symptoms and Signs Present on Admission

44. Inhaled Hypertonic Saline Plus rhDNase

45. Results

46. Abbreviations

47. Abbreviations (cont)

48. References

49. References (cont)

50. References (cont)

51. References (cont)

52. References (cont)